Psychiatry and Neurology, Neurology · Coeur D Alene, ID
NPI
1508286188
Since 2014
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
700 W Ironwood Dr Ste 158
Coeur D Alene, ID, 83814
Phone (208) 625-5100
Groups this clinician bills Medicare through
Medicare paid, 2024
$20K
373 services
Medicare patients, 2024
135
Average age 65
Drug cost, 2024
$6.3M
2,553 prescriptions
Company payments, 2025
$16K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nina S Bozinov was code G2211 (visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's), 122 times for 87 patients. In total Nina S Bozinov billed 373 services in 6 codes, and Medicare paid $20K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-24.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|---|---|---|---|---|
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 122 | 87 | $11.22 | $1,369 |
| 99215 Office E&M - Established | Facility | 111 | 86 | $96.16 | $11K |
| 99214 Office E&M - Established | Facility | 33 | 33 | $69.92 | $2,307 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 28 | 22 | $23.81 | $667 |
| 99205 Office E&M - New | Facility | 22 | 22 | $123.01 | $2,706 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 21 | 15 | $6.30 | $132 |
| 99215 Office E&M - Established | Office | 14 | 12 | $74.27 | $1,040 |
By year: 2022 $21K for 489 services; 2023 $19K for 251 services; 2024 $20K for 373 services.
Medicare prescription drug claims, 2024
In 2024, the drug Nina S Bozinov prescribed most often to Medicare patients was Kesimpta Pen (Ofatumumab), with 438 prescriptions and refills. In total Nina S Bozinov wrote 2,553 Medicare prescriptions that cost $6.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Kesimpta Pen Ofatumumab | 438 | 440 | 51 | $3.7M |
| Baclofen Generic | 253 | 380 | 48 | $7,447 |
| Gabapentin Generic | 213 | 373 | 38 | $7,092 |
| Duloxetine Hcl Generic | 175 | 266 | 25 | $3,597 |
| Tizanidine Hcl Generic | 116 | 193 | 27 | $1,506 |
| Dalfampridine Er Dalfampridine | 100 | 128 | 18 | $43K |
| Myrbetriq Mirabegron | 68 | 112 | 15 | $49K |
| Solifenacin Succinate Generic | 65 | 105 | 13 | $7,125 |
| Pregabalin Generic | 61 | 75 | 13 | $1,449 |
| Gemtesa Vibegron | 61 | 65 | Under 11 | $31K |
| Fingolimod Fingolimod Hcl | 46 | 46 | Under 11 | $12K |
| Dimethyl Fumarate Generic | 43 | 43 | Under 11 | $120K |
| Diazepam Generic | 43 | 43 | 16 | $226 |
| Glatiramer Acetate Generic | 35 | 35 | Under 11 | $49K |
| Modafinil Generic | 32 | 38 | Under 11 | $4,262 |
Brand drugs: 806 claims; generic drugs: 1,747 claims; opioid claims: 32.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nina S Bozinov $16K ($16K in general payments such as food, travel and fees) from 7 companies. The largest payer was Genentech USA, Inc. with $11K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.